Clinical Trial Update: Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update evaluating the long-term safety of Lutetium-177 vipivotide tetraxetan in participants with prostate cancer, sponsored by Novarti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Prostate Cancer | Phase 4 | Status: RECRUITING